https://vitalspanwire.com/news/ascletis-oral-amylin-asc36-us-phase-1-trialVitalspan Wireen2026-09-11T21:01:58.968ZAscletis starts U.S. trial of oral amylin peptide ASC36 for obesityhttps://vitalspanwire.com/news/loberamisal-lais-stroke-recovery-jamaVitalspan Wireen2026-09-11T16:02:39.257ZLoberamisal stroke trial reports better 90-day recovery, with confirmation neededhttps://vitalspanwire.com/news/redasemtide-phase-2b-stroke-endpoint-missVitalspan Wireen2026-09-10T21:01:56.535ZRedasemtide misses Phase 2b stroke endpoint, Shionogi reportshttps://vitalspanwire.com/news/dementia-prevention-social-environmental-risk-analysisVitalspan Wireen2026-09-10T16:02:42.257ZDementia prevention analysis calls for greater attention to social and environmental riskshttps://vitalspanwire.com/news/apoe-genetics-blood-biomarker-cognitive-decline-riskVitalspan Wireen2026-09-10T11:02:12.907ZAPOE genetics may sharpen blood-based estimates of cognitive decline risk